Prelude to buyout? Astellas picks up Taysha stock, two gene therapy programs for $50M
Half a year after Taysha Gene Therapies laid off 35% of its staffers and paused the bulk of its R&D work, the Dallas crew has secured a partner — and some cash — to support two main programs remaining in the pipeline.
Astellas is swooping in to acquire 15% of the biotech as well as an option to exclusively license TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy (GAN). The total investment comes to $50 million, a modest sum that reflects the financial predicament Taysha found itself in.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.